Micro<scp>RNA</scp>‐155: microtuning the allergic concert

Cortinas-Elizondo, Fabiola; Gunten, Stephan von

doi:10.1111/all.12673

Cited by 3 publications

(3 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultimately, they demonstrated that SOCS3 is upregulated in AR and targeted by miR30a-5p [51]. This work adds to emerging evidence that miRNAs play an important role in the orchestration of allergic disorders [52]. …”

Section: Allergic Rhinitismentioning

confidence: 87%

Recent Advances in Experimental Allergy

Adams

Gunten

2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Atopic disorders are on the rise and pose a great burden on society. A better understanding of the underlying mechanisms is required for the development of improved or novel therapeutic strategies. Here we aim to highlight recent advances in experimental allergy, with a particular focus on proposed treatment alternatives for airway disorders, atopic dermatitis, and food allergy. Furthermore, we discuss recent work focusing on molecular and cellular mechanisms that might offer candidates for future preventive or therapeutic intervention.

show abstract

Section: Allergic Rhinitismentioning

confidence: 87%

Recent Advances in Experimental Allergy

Adams

Gunten

2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…In addition, miRNA‐155 is essential to dendritic cells for the initiation and maintenance of allergic airway inflammation. The deficiency of miRNA‐155 can alleviate allergic airway inflammation by reducing Th2 immune reaction and ATP‐/P2R‐induced activation of dendritic cells in mice, which suggests that miRNA‐155 is a potential therapeutic target for allergic airway disease . The levels of miR‐92b, miR‐210, and miR‐34a in airway epithelial extracellular vesicles are significantly correlated with lung function parameters in children, and lower miRNA levels in nasal lavages are associated with airway obstruction .…”

Section: Risk Factorsmentioning

confidence: 99%

“…The deficiency of miRNA-155 can alleviate allergic airway inflammation by reducing Th2 immune reaction and ATP-/P2R-induced activation of dendritic cells in mice, which suggests that miRNA-155 is a potential therapeutic target for allergic airway disease. 28,29 The levels of miR-92b, miR-210, and miR-34a in airway epithelial extracellular vesicles are significantly correlated with lung function parameters in children, and lower miRNA levels in nasal lavages are associated with airway obstruction. 30 Epigenetic changes in AR patients, including up-or down-regulation of DNA methylation and microRNA levels, may be potential treatment targets in the future.…”

mentioning

confidence: 99%

Recent developments and highlights in allergic rhinitis

Meng

Wang

Zhang

2019

Allergy

125

105

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a disease with high prevalence all over the world and therefore needs to be thoroughly investigated and treated accordingly. The mechanisms underlying the pathology and treatment of AR have been widely studied, but many aspects remain unclear and warrant further investigations. This review presents an overview of recently published papers highlighting the risk factors, mechanisms, and treatment of AR. Additionally, recent studies discussing the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics in AR are also covered. K E Y W O R D Sallergic rhinitis, biologics, epigenetics, risk factors, treatment | 2321 MENG Et al.

show abstract

Allergy and Atopic Diseases: An Update on Experimental Evidence

Verschoor

Gunten²

2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Over the last decades, an increasing appearance of allergies and atopic disorders, such as asthma, dermatitis, and rhinitis, has been observed. The mechanisms of these disorders remain unclear, and therefore the development of novel therapies is limited. Current treatments are often symptomatic, nonspecific, or may have severe side effects. Further insights into the mechanisms of the underlying disease pathogenesis could reveal novel targets for treatment. In this review, we provide an update on recent basic and translational studies that offer novel insights and opportunities for the treatment of patients with atopic disorders.

show abstract

MicroRNA‐155: microtuning the allergic concert

Cited by 3 publications

References 15 publications

Recent Advances in Experimental Allergy

Recent Advances in Experimental Allergy

Recent developments and highlights in allergic rhinitis

Allergy and Atopic Diseases: An Update on Experimental Evidence

Contact Info

Product

Resources

About